| Literature DB >> 32023533 |
William G Wierda1, John C Byrd2, Jeremy S Abramson3, Syed F Bilgrami4, Greg Bociek5, Danielle Brander6, Jennifer Brown7, Asher A Chanan-Khan8, Julio C Chavez9, Steve E Coutre10, Randall S Davis11, Christopher D Fletcher12, Brian Hill13, Brad S Kahl14, Manali Kamdar15, Lawrence D Kaplan16, Nadia Khan17, Thomas J Kipps18, Megan S Lim19, Shuo Ma20, Sami Malek21, Anthony Mato22, Claudio Mosse23, Mazyar Shadman24, Tanya Siddiqi25, Deborah Stephens26, Suchitra Sundaram27, Nina Wagner28, Mary Dwyer29, Hema Sundar29.
Abstract
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in recent years because of the improved understanding of the disease biology and the development of novel targeted therapies. In patients with indications for initiating treatment, the selection of treatment should be based on the disease stage, patient's age and overall fitness (performance status and comorbid conditions), and cytogenetic abnormalities. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.Entities:
Year: 2020 PMID： 32023533 DOI： 10.6004/jnccn.2020.0006
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908